Lung Inflammation Clinical Trial
Official title:
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
Background: Respiratory diseases affect more than 1 billion people worldwide. They are a growing public health concern. The lungs are constantly exposed to environmental factors such as dust, fumes, microbes, and pollutants. But much is still not known about how these pollutants lead to respiratory illnesses. Researchers want to collect samples from lungs and blood to see how genetics and environmental pollutants affect cellular responses or functioning. Objectives: To study how cytochrome P450 epoxygenase pathway enzymes affect macrophage function in the lungs and inflammatory responses. Eligibility: Adults ages 18 65 who can have a bronchoscopy. Design: All study visits will take place at the NIEHS Clinical Research Unit in Research Triangle Park, NC. At study visit 1, participants will be screened with medical history and physical exam. They will have blood and urine tests. They will take tests that measure their lung function. They will answer questionnaires. Before the visit, they will be given a list of medicines they cannot take. They also must not have caffeine on the day of their visit. The visit will last about 3 hours. At study visit 2, participants will give blood samples. They will undergo bronchoscopy. For this, they will get an intravenous line in a vein to get sedatives. Their airways will be numbed. Cells will be collected from their lungs. They will fast for 8 hours before the visit. They must have someone else drive them home from the visit. The visit will last about 3-4 hours. Participants will get a follow-up phone call about 1 day after study visit 2.
This is a prospective, cross-sectional study designed to provide a consistent method for obtaining biological samples and respiratory health-related information from participants for use in research that evaluates lung function (e.g., responses to environmental agents such as air pollution particles, engineered nanomaterials, or immune ligands; the role of genetics on cellular responses or functioning). Study participants will be adult volunteers, ages 18-65 (inclusive), who meet eligibility criteria to undergo bronchoscopy. Potential participants will be prescreened and scheduled for a final eligibility visit that will include medical history review, vital signs, physical examination, blood draw, and pulmonary function tests. After eligibility is confirmed, the participant will be scheduled for biological sample collections, which will include a blood draw and bronchoscopy. The objective of this protocol is to investigate the role of cytochrome P450 (CYP) epoxygenase pathway enzymes, including the soluble epoxide hydrolase (sEH; encoded by EPHX2) and CYP2J2 proteins, in macrophage function and inflammatory responses. The primary outcome measure will evaluate macrophage phagocytosis in an ex vivo assay, comparing groups of individuals with and without EPHX2 and CYP2J2 polymorphisms of interest. Secondary outcomes will include evaluations of ex vivo gene expression of inflammatory receptors and cytokines in stimulated macrophages (alveolar and peripheral blood monocyte-derived), assessment of the lower airway microbiome from bronchoalveolar lavage (BAL) fluid, and measurement of eicosanoids and cytokines in serum and BAL fluid. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
Completed |
NCT02277002 -
Commuter Air Pollution Intervention Study
|
N/A | |
Completed |
NCT05260827 -
The Effects of Heated Tobacco Products Use on Lung Function and Volatile Organic Compounds in Exhaled Air
|
N/A | |
Completed |
NCT04606069 -
Treat COVID-19 Patients With Regadenoson
|
Phase 1/Phase 2 | |
Completed |
NCT02151552 -
Assessing NOS Uptake With PET Imaging in Lung Inflammation
|
Early Phase 1 | |
Recruiting |
NCT05854563 -
Cough Capture as a Portal Into the Lung
|
||
Active, not recruiting |
NCT05752019 -
TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era
|
||
Completed |
NCT00741013 -
Quantifying Airway Inflammation With Radiologic Tests
|
Phase 0 | |
Completed |
NCT01174056 -
Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging
|
Phase 0 | |
Recruiting |
NCT04755478 -
LUS to Assess Lung Injury After Lung Lobectomy
|
||
Completed |
NCT03905837 -
Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
|
Phase 4 | |
Recruiting |
NCT03312712 -
Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation
|
||
Recruiting |
NCT03492762 -
PET Imaging CCR2 in Lung Inflammation
|
Early Phase 1 | |
Recruiting |
NCT04677309 -
LUS to Assess Lung Injury After Lung Resection
|
||
Terminated |
NCT02848586 -
Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers
|
N/A | |
Enrolling by invitation |
NCT04781153 -
Bergen Oral Respiratory Intervention Study
|
N/A | |
Withdrawn |
NCT04782700 -
P-Co-Li (Pulmonary Covid-19 Study)
|
N/A |